Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00108_DB00290_nanopub.RAE2vMqUtCAIYfIYZHwprxi8hOge6wzzbzhjvINgPlE6E#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00108_DB00290 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00108_DB00290 label "DDI between Natalizumab and Bleomycin - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants. [drugbank_resource:DB00108_DB00290]" assertion.
- drugbank_resource:DB00108_DB00290 identifier "drugbank_resource:DB00108_DB00290" assertion.
- drugbank_resource:DB00108_DB00290 title "DDI between Natalizumab and Bleomycin - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants." assertion.
- drugbank:DB00108 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB00290 assertion.
- drugbank:DB00290 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00108_DB00290 assertion.